Abstract
Supralethal doses of chemoradiotherapy followed by allogeneic bone marrow transplantation are being used to treat patients with acute leukaemia refractory to conventional chemotherapy regimens1–5. Despite this approach, leukaemia has recurred in about one-third of the patients1–5. One strategy to solve this problem would be to transplant marrow with antileukaemic reactivity to obtain a graft-versus-leukaemia (GvL) effect against residual leukaemia cells6. Many workers have demonstrated antileukaemic effects following transplantation of immunocompetent cells from allogeneic donors in animal models, but graft-versus-host (GvH) disease proved to be a complication6–8. Recently, Weiden et al.9 presented evidence of a GvL effect in human recipients of marrow grafts from HLA compatible allogeneic donors. Unfortunately, this antileukaemic effect was associated with moderate, severe or lethal GvH disease, and the lower probability of recurrent leukaemia was offset by a higher probability of GvH-related mortality9. We report here the results that suggest a clinically feasible method of obtaining desired GvL effects while avoiding undesired GvH reactions. Alloimmunisation of CBA (H–2k) mice was found to induce a population of cells which, when transplanted into leukaemic AKR (H–2k) mice, led to the destruction of disseminated leukaemia (AKR-L) cells. Furthermore, the transplanted cells caused no augmentation in the mild GvH disease observed when cells from unimmunised CBA donors were administered to lethally irradiated non-leukaemic AKR hosts.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Thomas, E. D. et al. Blood 49, 511–532 (1977).
Editorial Lancet ii, 392 (1977).
Gale, R. P. et al. Lancet ii, 1197–1200 (1977).
Santos, G. W. Transplantn Proc. 10, 173–175 (1978).
Bortin, M. M. et al. J. Am. med. Ass. 240, 1245–1252 (1978).
Bortin, M. M., Truitt, R. L. & Rimm, A. A. in The Handbook of Cancer Immunology, Vol. 5, (ed. Waters, H.) 403–430 (Garland, New York, 1978).
Fefer, A., Einstein, A. B., Jr & Cheever, M. A. Ann. N.Y. Acad. Sci. 277, 492–504 (1976).
Truitt, R. L. in Experimental Hematology Today – 1978 (eds Baum, S.J. & Ledney, G.D.) 195–201 (Springer, Berlin, 1978).
Weiden, P. L. et al. New Engl. J. Med. 300, 1068–1073 (1979).
Bortin, M. M., Rimm, A. A. & Saltzstein, E. C. Science 179, 811–813 (1973).
Herberman, R. B., Nunn, M. E. & Holden, H. T. J. Immun. 121, 304–309 (1978).
Herberman, R. B., Nunn, M. E., Holden, H. T. & Djeu, J. Y. Int. J. Cancer 19, 555–564 (1977).
Bach, M. L., Bach, F. H. & Zarling, J. M. Lancet i, 20–22 (1978).
Zarling, J.M., Robins, H.I., Raich, P.C., Bach, F.H. & Bach, M.L. Nature 274, 269–271 (1978).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Bortin, M., Truitt, R., Rimm, A. et al. Graft-versus-leukaemia reactivity induced by alloimmunisation without augmentation of graft-versus-host reactivity. Nature 281, 490–491 (1979). https://doi.org/10.1038/281490a0
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/281490a0
This article is cited by
-
Next generation HLA-haploidentical HSCT
Bone Marrow Transplantation (2015)
-
The graft-versus-lymphoma effect: clinical review and future opportunities
Bone Marrow Transplantation (2005)
-
T cell-mediated graft-versus-leukemia reactions after allogeneic stem cell transplantation
Cancer Immunology, Immunotherapy (2005)
-
Reduced-intensity stem cell transplantation from an HLA-identical sibling donor in patients with myeloid malignancies
Bone Marrow Transplantation (2004)
-
Graft-versus-Host Disease, the Graft-versus-Leukemia Effect, and Mixed Chimerism following Nonmyeloablative Stem Cell Transplantation
International Journal of Hematology (2003)
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.